Rating Change
HC Wainwright & Co. reiterated its Neutral rating on Summit Therapeutics Inc. (NASDAQ:SMMT) on August 18, 2026.
reiterateNASDAQ:SMMT
HC Wainwright & Co. Reiterates Neutral Rating on Summit Therapeutics Inc. (SMMT)
HC Wainwright & Co. reiterated its Neutral rating on Summit Therapeutics Inc.
At publication ·
What changed
Summit Therapeutics Inc. (NASDAQ:SMMT) · reiterate
- Firm
- HC Wainwright & Co.
- Rating
- Neutral to Neutral
- Price at event
- $12.82
- Market capitalization
- $13.4B
At a glance
Key takeaways
- HC Wainwright & Co. reiterated a Neutral rating on Summit Therapeutics Inc. (SMMT) on August 18, 2026, with the stock trading at $12.82 and a market capitalization of $13.4 billion.
Market Context
Summit Therapeutics Inc. operates in the Healthcare sector. The stock currently trades at $12.82 with a market capitalization of $13.4B. The stock has declined 51.1% over the past 52 weeks.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Summit Therapeutics Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Summit Therapeutics Inc.
Among the 10 most recent ratings: 4 Buy, 5 Hold, 1 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 18, 2026 | HC Wainwright & Co. | Neutral | N/A |
| Aug 12, 2026 | Leerink Partners | Market Perform | N/A |
| Jul 24, 2026 | Stifel | Buy | N/A |
| Jul 24, 2026 | Guggenheim | Buy | N/A |
| Jul 23, 2026 | HC Wainwright & Co. | Neutral | N/A |
Related Tools: Analyst Ratings Dashboard | View SMMT Stock Page
Frequently Asked Questions
What does the Neutral rating mean for SMMT?
A rating of Neutral from HC Wainwright & Co. reflects the analyst's outlook on Summit Therapeutics Inc. (NASDAQ:SMMT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the SMMT forecast page.